



Corp. Off.:- 201, "The Summit Business Bay"
Behind Guru Nanak Petrol Pump,
Off Andheri Kurla Road, Andheri (E),
Mumbai - 400 093 (India)
Ph. : +91 22 69073100

18th November, 2023

BSE Limited

Phiroze Jeejeebhoy Towers
Dalal Street
Mumbai-400001
Stock Symbol-533543

National Stock Exchange of India Ltd.

Exchange Plaza, C-1, Block G
Bandra Kurla Complex
Bandra (E), Mumbai-400051
Scrip Code- BROOKS

Dear Sir/Madam,

Sub: Disclosure under Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015

This refers to the requirement under proviso to Regulation 30 of SEBI (Listing Obligations and Disclosure Requirement) Regulations, 2015. We are enclosing herewith details of current status of individual litigations of the Company.

Thanking You,
Yours faithfully

For **BROOKS LABORATORIES LIMITED**

A handwritten signature in blue ink, appearing to read "Jai Vaidya", is written over the typed name.


Jai Vaidya
Company Secretary & Compliance Officer
Encl: As above



Annexure A – Litigations

Sl.	Name of the opposing party	Court/ Tribunal/ Agency where litigation is filed	Brief details of the dispute/ litigation	Assessment Year (AY)	Expected financial implications, if any, due to compensation, penalty etc*	Quantum of claims, if any#
1	Income tax Department	Income Tax Appellate Tribunal, Chandigarh	Brooks Laboratories Limited filed appeals with the ITAT against partly disallowed order passed by CIT A PANCHKULA Dated 14/08/2023.	AY 2012-13	The expected financial implication cannot be determined at this stage as the matter is currently pending before authority.	The quantum of claim will be dependent upon the outcome of the litigation. As on date.
2	Income tax Department	CIT A PANCHKULA	Brooks Laboratories Limited filed appeals with the CIT A PANCHKULA against the order passed by ACIT PKL CIRCLE PANCHKULA Under section 143(3) dated 26/02/2016.	AY 2013-14	NIL Rs.339.50 Lakhs is disclosed as contingent Liability in the Financial Statements till 31st March 2023.	The quantum of claim will be dependent upon the outcome of the litigation. As on date.
3	Income tax Department	Income Tax Appellate Tribunal, Chandigarh	Brooks Laboratories Limited filed appeals with the ITAT against the partly disallowed order passed by CIT A PANCHKULA Dated 06/07/2023.	AY 2014-15	NIL Rs.142.85 Lakhs is disclosed as contingent Liability in the Financial Statements till 31st March 2023.	The quantum of claim will be dependent upon the outcome of the litigation. As on date.
4	Income tax Department	CIT A PANCHKULA	Brooks Laboratories Limited filed appeals with the CIT A PANCHKULA against the order passed by ACIT PKL CIRCLE PANCHKULA Under section 143(3) dated 10/11/2017.	AY 2015-16	NIL Rs.0.68 Lakhs is disclosed as contingent Liability in the Financial Statements till 31st March 2023.	The quantum of claim will be dependent upon the outcome of the litigation. As on date.
5	Income tax Department	Income Tax Appellate Tribunal, Chandigarh	Brooks Laboratories Limited filed appeals with the ITAT against the partly disallowed order passed by CIT A PANCHKULA Dated 14/08/2023.	AY 2016-17	NIL Rs.73.45 Lakhs is disclosed as contingent Liability in the Financial Statements till 31st March 2023.	The quantum of claim will be dependent upon the outcome of the litigation. As on date.
6	The Drug Inspector, Food and Administration vide State of Maharashtra	Additional Chief Judicial magistrate Nagpur Court	under section 32 read with 18(a)(i) read with section 16 and 34, punishable under section 27(d) of the Drugs and Cosmetics Act, 1940 for manufacturing and selling GoClav 625 Tablets manufactured in the month of March 2015 allegedly 'of not standard quality' for the reasons that "The total Viable Count of Lactic Acid Bacillus is Less (18.33 % of the labelled amount) than the permissible limit	NA	The expected financial implication cannot be determined at this stage as the matter is currently pending before the court.	The quantum of claim will be dependent upon the outcome of the litigation. As on date.

Jai



7	The Drug Inspector, Food and Administration vide Union of India	Haridwar Chief Judicial magistrate	under section 32 read with 18(a)(i) read with section 16 and 17(A), punishable under section 27(b)(i) and 27(d) of the Drugs and Cosmetics Act, 1940 for selling Polytaz 1.125 (Certrioxone & Tazobactum (for injection) manufactured in the month of July 2013 allegedly 'of not standard quality' for the reasons that the samples do not confirms to claim as per IP 2010 in respect to the "Particulate matter & Clarity of the solution".	NA	The expected financial implication cannot be determined at this stage as the matter is currently pending before the court.	The quantum of claim will be dependent upon the outcome of the litigation. As on date.
8	The Drug Inspector, Food and Administration, MS Thane vide Union of India	Hon'ble Chief Judicial magistrate, Thane	under section 32 read with 18(a)(i) read with section 16(1)(a) and 34, punishable under section 27(d) of the Drugs and Cosmetics Act, 1940 for manufacturing and selling FORTICLAV DRY SYRUP (Amoxycillin and Potassium Clavulanate Oral Suspension IP: Batch No. FDS 8065, Manufacturing date June 1, 2008 Expiry Date November 30, 2009) allegedly 'of not standard quality' for the reasons that the samples do not confirms to claim as per IP 2007	NA	The expected financial implication cannot be determined at this stage as the matter is currently pending before the court.	The quantum of claim will be dependent upon the outcome of the litigation. As on date.

Jai

